The premise that artificial intelligence (AI) can help drug developers identify other uses for existing therapies – rather than making big outlays to find new ones - and also help to direct scientists to the most promising discoveries more quickly, lies behind a new collaboration between BenevolentAI and the UK life science medical research charity MRC Technology (MRCT).
BenevolentAI, which describes itself as the largest private AI company in Europe, has teamed up with MRCT to explore drug...